|Nasdaq:||GOOG NFLX BIIB IBB AMZN TSLA ALXN ILMN WYNN AMGN GMCR SLXP COST GILD AAPL CELG WDC SNDK INTU|
|Nyse:||ACT V MCK LNKD IVV AGN LMT GS PXD SPG FDX IBM MMM CMI TWC GD NOC APD BDX PH|
|New Highs:||IBB V ILMN ALXN LMT ORLY WHR AMGN MMM GMCR GD NOC HUM COST BXP EW SLG SBAC GILD SRE|
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.